BRCA1 and pancreatic neoplasm: The IC50 of Olaparib on BRCA1/2-proficient human pancreatic cancer MIA PaCa-2 and PANC-1 cell lines was 200 μM, while the IC50 of Niraparib was 26 μM and 50 μM, respectively.